

Icanemab-irmb (Leqembi)

REFERRAL STATUS: New Referral Dose or Frequency Change Order Renewal

Infusion Office Preference: _____

PATIENT INFORMATION			
Date:	Patient Name:	DOB:	
<input type="checkbox"/> NKDA Allergies:	Weight (lbs / kg):	Height:	
Patient Status: <input type="checkbox"/> New to Therapy <input type="checkbox"/> Continuing Therapy - Last Treatment Date:		Next Due Date:	
DIAGNOSIS AND ICD 10 CODE			
<input type="checkbox"/> Alzheimer's disease with early onset	ICD 10 Code: G30.0		
<input type="checkbox"/> Mild Cognitive Impairment, So stated	ICD 10 Code: G31.84		
<input type="checkbox"/> other ICD10 Code:)	Description:		
G30.X CODES BELOW REQUIRE SECONDARY F02.8x DIAGNOSIS CODE- PLEASE SELECT ONE FROM EACH COLUMN			
→		<u>Secondary</u>	
<input type="checkbox"/> G30.1 Alzheimer's disease late onset	<input type="checkbox"/> F02.80 Dementia without behavioral disturbance		
<input type="checkbox"/> G30.8 Other Alzheimer's disease	<input type="checkbox"/> F02.81 Dementia with behavioral disturbance		
<input type="checkbox"/> G30.9 Alzheimer's disease , unspecified			
REQUIRED DOCUMENTATION			
<input type="checkbox"/> This signed order form by the provider <input type="checkbox"/> Patient demographics AND insurance info <input type="checkbox"/> Clinical/Progress notes			
Prescriber must indicate that the following requirements have been met (provide supporting documentation)			
<input type="checkbox"/> Beta Amyloid Pathology Confirmed via:			
↳ <input type="checkbox"/> Amyloid PET Scan OR <input type="checkbox"/> CFS Analysis-Date: _____ Result: _____			
<input type="checkbox"/> Cognitive Assessment Used: _____ Date: _____ Result: _____			
<input type="checkbox"/> ApoE εε4 Genetic Test - Date: _____ Result: <input type="checkbox"/> Homozygote <input type="checkbox"/> Heterozygote <input type="checkbox"/> Noncarrier			
MEDICARE REGISTRATION # IF APPLICABLE _____			
MEDICATION ORDERS(Note: Only one stage of treatment may be ordered at a time			
<input type="checkbox"/> Stage 1 (Infusions #1-4) ✓ Leqembi 10mg/kg IV every two weeks x 4 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> MRI of brain within one year prior to first infusion. Date of MRI: o By checking this box, I confirm that Beta Amyloid Pathology has been confirmed via CSF or PET.	<input type="checkbox"/> Stage 2 (Infusions #5 and #6) ✓ Leqembi 10mg/kg IV every two weeks x 2 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #5. I have reviewed the results and clear patient to proceed with infusions #5 and #6.	<input type="checkbox"/> Stage 3 (Infusions #7-13) ✓ Leqembi 10mg/kg IV every two weeks x 7 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #7. I have reviewed the results and clear patient to proceed with infusions #7 through #13.	<input type="checkbox"/> Stage 4 (Infusions #14 & beyond) ✓ Leqembi 10mg/kg IV every two weeks x doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #14. I have reviewed the results and clear patient to proceed with infusions #14 and beyond as ordered above

Fax referral to 866-507-1164 or email to bionurses@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become part of the patient's medical record.

PRE-INFUSION :

- Confirm baseline MRI results prior to initiation of treatment
- Confirm MRI completed and reviewed by prescriber prior to the 5th, 7th, and 14th treatment
- Measure and record weight prior to each treatment to determine dose
- Hold infusion and notify provider if patient reports:
 - Headache
 - Dizziness
 - Nausea
 - Vision Changes
 - New or worsening confusion

Post -INFUSION :

- Educate patient/care partner to report headache, dizziness, nausea, vision changes, or new/worsening confusion.
- Fax infusion record to provider below :

PRESCRIBER INFORMATION

Provider Name (print)	Provider Signature**:	Date:
Office Phone	Office Fax	

***Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. Referring physician to monitor patient*

Fax referral to 866-507-1164 or email to bionurses@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become part of the patient's medical record.

Created 11/22/23